SPDR S&P Pharmaceuticals ETF
XPH
XPH
72 hedge funds and large institutions have $108M invested in SPDR S&P Pharmaceuticals ETF in 2022 Q4 according to their latest regulatory filings, with 18 funds opening new positions, 15 increasing their positions, 19 reducing their positions, and 10 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
less ownership
Funds ownership: →
less capital invested
Capital invested by funds: $ → $
13% less call options, than puts
Call options by funds: $901K | Put options by funds: $1.04M
21% less repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 19
Holders
72
Holding in Top 10
–
Calls
$901K
Puts
$1.04M
Top Buyers
| 1 | +$5.35M | |
| 2 | +$4.92M | |
| 3 | +$2.99M | |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$1.84M |
| 5 |
HighTower Advisors
Chicago,
Illinois
|
+$1.46M |
Top Sellers
| 1 | -$13.6M | |
| 2 | -$5.68M | |
| 3 | -$3.17M | |
| 4 |
Ameriprise
Minneapolis,
Minnesota
|
-$2.1M |
| 5 |
LPL Financial
San Diego,
California
|
-$743K |